COMP <GO>
TELA vs DXR // EV/EBITDA & P/E VALUATION
TELA Bio Inc. (NASDAQ) VS. Daxor Corporation (NASDAQ) • 15-METRIC TALLY: TELA 0
— DXR 2
■ METRIC PARITY
LAST: $0.92 (-5.74%) • MKT CAP: $41.5M
valuation
—
LAST: $8.92 (-0.56%) • MKT CAP: $52.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TELA VS. DXR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TELA | DXR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -42.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -48.30% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 15.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.8 | 35.4 | -1.61 | DXR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $41.5M | $52.1M | -$10.5M | DXR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TELA REV | DXR REV | TELA GROSS % | DXR GROSS % | TELA FCF | DXR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $80.3M | — | 67.7% | — | -$28.7M | — |
| FY 2024 | $69.3M | — | 67.1% | — | -$42.6M | — |
| FY 2023 | $58.5M | — | — | — | -$40.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TELA // BETA —
DXR // BETA —